What: Shares of Alkermes (NASDAQ: ALKS) shed up to 43 % of their value on extraordinary volume in
early morning trading today after the company announced that its orally administered drug ALKS - 5461, indicated for major depressive disorder (MDD), failed to meet its primary endpoints in two late - stage studies.